Search
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the … Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1).
Synonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1Mitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper … Tract Urothelial Cancer (LG-UTUC)[L12867] - as well as adjunctly to _ab externo_ glaucoma surgeries.
Categories: Compounds used in a research, industrial, or household settingProducts: MITONCO 10mg powder for solution for injection/infusion or intravesical, Mitomycin for InjectionBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve … Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension.
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Categories: Experimental Unapproved Treatments for COVID-19Bordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONArbutamine
go.drugbank.com/drugs/DB01102Approveddiagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately . … Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in
Categories: Compounds used in a research, industrial, or household settingMifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalMifepristone is a progestational and glucocorticoid hormone antagonist. … Currently under investigation for use in psychotic depression (phase 3 trials).
Categories: Hormonal Contraceptives for Systemic UseTechnetium Tc-99m exametazime
go.drugbank.com/drugs/DB09163ApprovedExametazime, also known as hexamethylpropyleneamine oxime or HMPAO, acts as a chelating agent for the Tc-99m radioisotope. … It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease.
Categories: Compounds used in a research, industrial, or household settingCalcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawnCalcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it. … [A31516] This drug was developed by Lederle Cyanamid Canada Inc and approved for marketing in Canada in 1959. The current status of calcium carbimide is cancelled post marketing.[L1113]